P2-003

N/A

Report date: 2022/04/11 17:52:57

Base Information

Drug NameP2-003

Drug Alias NameClaudin 18.2 Dual CAR-TP2-003P-2003

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CLDN18T lymphocyte replacements

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsPancreatic NeoplasmsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShandong Boan Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShandong Boan Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A